European study of ambulatory management of heart failure by cardiologists;Estudio europeo del tratamiento ambulatorio de la insuficiencia cardíaca realizado por cardiólogos

Revista Espanola de Cardiologia

Volumn 57, Issue 12, 2004, Pages 1170-1178

  Salvador Taboada, María J ^a   Sebaoun, Alain ^b   Sonntag, Frank ^b   Blanch, Pedro ^b   Silber, Sigmund ^b   Aznar, Joaquín ^b   Komajda, Michel ^b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b NONE

Author keywords

Drugs; Epidemiology; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG HYPERSENSITIVITY; DRUG USE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FRANCE; GEOGRAPHY; GERMANY; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTPATIENT; PRESCRIPTION; PREVALENCE; QUESTIONNAIRE; SPAIN;

EID: 12544259697     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13069863     Document Type: Article

References (32)

1. Rodríguez Artalejo F, Guallar-Castillón P, Banegas Banegas JR, Del Rey Calero J. Trends in hospitalization and mortality for Heart failure in Spain, 1980-1993. Eur Heart J 1997;17:71-9.
2. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:15-21.
3. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-23.
4. Cleland JGF, Khand A, Clark AL. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.
5. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
6. Davie AP, McMurray JJ. ACE inhibitors and health-care economics. Coron Artery Dis 1995;6:315-9.
7. Navarro-López F, De Teresa E, López-Sendón JL, Castro-Beiras A, y Grupo de Trabajo de insuficiencia cardíaca de la Sociedad Española de Cardiología. Guías del diagnóstico, clasificación y tratamiento de la IC y del shock cardiogénico. Rev Esp Cardiol 1999;52(Supl 2):1-49.
8. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet 1998; 352(Suppl):14.
9. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
10. Davie AP, McMurray JJ. ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians? Postgrad Med J 1999;75:219-22.
11. Hillis GS, Al-Mohammad A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996;76:427-9.
12. Clark AL, Coats AJS. Severity of heart failure and dosages of angiotensin converting enzyme inhibitors. BMJ 1996;310:973-4.
13. Gambassi G, Forman DE, Laplane KL, Mor V, Sgadari A, Lipsitz LA, et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spred? The SAGE Study Group. Am Heart J 2000;139:85-93.
14. Bellotti P, Badano LP, Acquarone N, Griffo R, Lo Pinto G, Maggioni AP, et al. Specialty-related differences in the epidemiology, clinical profile, management and outcome patients hospitalised for heart failure. The OSCUR study. Eur Heart J 2001;22:596-604.
15. MacIntyre K, Capewell S, Stewart S, Chalmers JWT, Boyd J, Finalyson A, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.
16. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-63.
17. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-74.
18. Cleland JGF, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Eastaugh J, Follath F, et al. An international survey of the management of heart failure in primary care. The IMPROVEMENT of Heart Failure Programme. Lancet 2002;360:1631-9.
19. Rodríguez-Artalejo F, Banegas J, Guallar-Castillón P. Avances en el tratamiento de la instificiencia cardíaca (I). Epidemiología de la insuficiencia cardíaca. Rev Esp Cardiol 2004;57:163-70.
20. Segovia J, Alonso-Pulpón L, Peraira R, Silva L. Avances en el tratamiento de la insuficiencia cardíaca (II). Etiologí a y evaluación diagnóstica de la insuficiencia cardí aca. Rev Esp Cardiol 2004;57:250-9.
21. Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G. A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. Eur Heart J 2000;21:763-9.
22. Komajda M, Bouhour JB, Amouyel P, Delahaye F, Vicaut E, Croce I, et al. Ambulatory heart failure management in private practice in France. Eur Heart J Fail 2001;3:503-7.
23. Taubert G, Bergmeier C, Andresen H, Senges J, Potratz J. Clinical profile and management of heart failure: rural community hospital vs metropolitan heart center. Eur J Heart Fail 2001; 3:611-7.
24. Krum H, Tonkin AM, Currie J, Djundjek R, Johnston CI. Chronic heart failure in Australian general practice. The cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust 2001;174:439-44.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
26. Digitalis Intervention Group. The effect of digoxin en mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
27. Toal M, Walker R. Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice in North Cumbria. Eur J Heart Fail 2000;2:201-7.
28. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77: 832-8.
29. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilisation in heart failure in a community setting. Clin Cardiol 1998;21:103-8.
30. Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, et al, and the EPICAL investigators. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: the EPICAL Study. J Am Coll Cardiol 1999;33:734-42.
31. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Lancet 1999;353:9-13.
32. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-7.